TB-500 vs full thymosin beta-4: what's the difference?
TB-500 is a 17-amino-acid fragment of the full 43-amino-acid thymosin beta-4 protein. The structural, functional, and clinical differences explained.
Updated May 7, 2026 · 4 min read
TB-500 and thymosin beta-4 (TB4) are often used interchangeably in marketing, but they are not the same molecule. TB-500 is a 17-amino-acid fragment of the full 43-amino-acid TB4 protein. The fragment retains the central actin-binding domain and produces some of the same effects, but it isn't a one-to-one substitute for the parent protein.
This distinction matters when reading research — most peer-reviewed clinical literature on cardiac repair, corneal healing, or stroke recovery refers to the full TB4 protein, not the fragment.
The structural difference
| Property | TB-500 (fragment) | Full thymosin beta-4 (TB4) |
|---|---|---|
| Length | 17 amino acids | 43 amino acids |
| Source | Synthetic | Naturally occurring; also synthetic |
| Actin-binding domain | Yes (residues 17–23 of TB4) | Yes (residues 17–23) |
| N-terminal region (1–4) | Absent | Present — Ac-SDKP tetrapeptide |
| C-terminal region | Absent | Present |
| Manufacturing cost | Low | High |
| Commercial availability | Widespread (research-chem) | Limited (research, clinical supply) |
| Per-mg cost | ~$30–60 | ~$500+ |
The 17-amino-acid TB-500 fragment is sometimes called "TB-500" or "TB4 (17-23)." It's the central active region — the portion that binds and regulates G-actin.
What the fragment retains
TB-500 retains the actin-binding function of TB4. That's the mechanism most commonly cited for soft-tissue recovery:
- Sequestering G-actin (the building block of the cytoskeleton)
- Releasing it when needed for cell movement, division, or repair
- Modulating the cellular response to injury
For musculoskeletal recovery — tendon, ligament, muscle — the actin-binding function is the dominant mechanism. TB-500 retains it.
What the fragment loses
The full TB4 protein has functions beyond actin binding that the fragment doesn't replicate:
- Ac-SDKP tetrapeptide release — the N-terminal four amino acids of TB4 are cleaved off in the body to produce Ac-SDKP, an independent signaling peptide with anti-fibrotic and hematopoietic effects
- Direct binding to other proteins — TB4 has interactions beyond G-actin that involve regions outside the central fragment
- Distinct receptor signaling — emerging research suggests TB4 may interact with specific receptors that the fragment doesn't engage as effectively
For cardiac regeneration, anti-fibrotic effects, and certain immune-modulation pathways, full TB4 has data the fragment doesn't.
Why the fragment exists
Two practical reasons:
- Cost. Manufacturing 43-amino-acid peptides is significantly more expensive than 17-amino-acid peptides. TB-500 is roughly 10x cheaper per mg than full TB4.
- Sufficient activity. For musculoskeletal recovery — the use case most strength-peptide users care about — the fragment captures most of the relevant activity.
For research-chemical-grade strength peptides, the fragment is the practical choice. The full protein is reserved for clinical research where the additional functions matter.
How to know what you're buying
Vendor labeling is inconsistent. To verify what's in the vial:
- Check the COA's mass spectrometry result — TB-500 fragment has a characteristic mass (~1924 Da); full TB4 is ~4963 Da. The mass tells you what you have.
- Check the price per mg — full TB4 at $30/mg is almost certainly mislabeled fragment
- Check the source description — "TB4 fragment 17-23" or "Ac-LKKTETQ peptide" is the fragment; "thymosin beta-4 full sequence" is the full protein
- Ask the vendor directly — a reputable vendor will know
Research context — when the difference matters
When you read pre-clinical or clinical literature, pay attention to which molecule was used:
| Indication | Most-cited research uses | Fragment likely sufficient? |
|---|---|---|
| Skeletal muscle injury | Both | Yes |
| Tendon and ligament healing | Both | Yes |
| Cardiac tissue regeneration | Full TB4 (clinical trials) | Unclear — much of the cardiac data uses full TB4 |
| Corneal wound healing | Full TB4 (FDA Phase 3) | Unclear |
| Stroke / neural recovery | Full TB4 | Probably not |
| Anti-fibrotic effects | Full TB4 (Ac-SDKP cleavage) | No — fragment doesn't release Ac-SDKP |
| Hair growth | Mixed | Unclear |
For the strength-community uses (musculoskeletal recovery), TB-500 fragment captures the relevant biology. For specialized indications outside that use case, the parent protein has data the fragment doesn't.
What this means for protocol decisions
Practical implications:
- For tendon/ligament/muscle recovery, the standard TB-500 fragment is appropriate
- For broader anti-fibrotic or cardiac goals, the literature is on full TB4 — not directly translatable to fragment dosing
- Pricing should reflect the molecule — if a vendor charges full-TB4 prices for fragment, you're being overcharged
- Don't assume fragment trials match TB4 trials — when reading research, verify which molecule was used
The Ac-SDKP question
The N-terminal Ac-SDKP tetrapeptide that TB-500 doesn't include is itself a researched compound — sometimes sold separately under that name. It has independent anti-fibrotic and hematopoietic activity. Some users stack TB-500 with Ac-SDKP to recreate the activity profile of full TB4.
This is uncommon and not well-supported by user experience reports. If your goal genuinely calls for full TB4 activity, sourcing the full protein is more straightforward than reconstructing it.